Search alternatives:
2016 decrease » 026 decrease (Expand Search)
nm decrease » nn decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
_ decrease » _ decreased (Expand Search)
_ 2016 » _ 2019 (Expand Search), _ 2015 (Expand Search), _ 2010 (Expand Search)
12 nm » 10 nm (Expand Search), 12 mm (Expand Search), 12 m (Expand Search)
2016 decrease » 026 decrease (Expand Search)
nm decrease » nn decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
_ decrease » _ decreased (Expand Search)
_ 2016 » _ 2019 (Expand Search), _ 2015 (Expand Search), _ 2010 (Expand Search)
12 nm » 10 nm (Expand Search), 12 mm (Expand Search), 12 m (Expand Search)
-
1
-
2
-
3
-
4
-
5
Scatter plot for the absolute decrease in CS rates (A) and the relative decrease in CS rates (B) from 2008 to 2016 among hospitals in Guangzhou grouped by their baseline CS rates.
Published 2019“…One circle represents one hospital, with blue (<i>n</i> = 20), green (<i>n</i> = 36), orange (<i>n</i> = 34), and purple (<i>n</i> = 22) representing baseline CS rates of <30%, 30%–39%, 40%–49%, and ≥50%, respectively. The absolute decrease = the CS rate at baseline − the CS rate in Stage 2; the relative decrease = (the CS rate at baseline − the CS rate in Stage 2) ÷ the CS rate at baseline. …”
-
6
-
7
-
8
Ofd1 protection of photoreceptors from oxidative stress via decreasing ROS production.
Published 2016“…<p>(A) The intracellular oxidant DCFH of MNU-induced ROS in 661W cells observed by green fluorescence using Leica fluorescence microscope (with monochromatic CCD), and measured using fluorometer at wavelength of 488/525 nm. …”
-
9
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20